Use of secukinumab in a pediatric patient leads to significant improvement in nail psoriasis and psoriatic arthritis

Leah Ellis Wells; Tyler Evans; Rachael Hilton; Lara Wine Lee; Natasha Ruth

doi:10.1111/pde.13767

Use of secukinumab in a pediatric patient leads to significant improvement in nail psoriasis and psoriatic arthritis

Pediatr Dermatol. 2019 May;36(3):384-385. doi: 10.1111/pde.13767. Epub 2019 Feb 27.

Authors

Leah Ellis Wells¹, Tyler Evans², Rachael Hilton³, Lara Wine Lee⁴, Natasha Ruth⁵

Affiliations

¹ Mercer University School of Medicine, Macon, Georgia.
² University of Nebraska College of Medicine, Omaha, Nebraska.
³ Medical University of South Carolina, Charleston, South Carolina.
⁴ Pediatric Dermatology, Medical University of South Carolina, Charleston, South Carolina.
⁵ Pediatric Rheumatology, Medical University of South Carolina, Charleston, South Carolina.

PMID: 30811618
DOI: 10.1111/pde.13767

Abstract

Many pediatric psoriasis patients suffer from nail involvement and psoriatic arthritis. In adults, biologic agents have demonstrated success in treating refractory nail psoriasis and arthritis, but studies are limited in children. In this report, we present a pediatric patient with severe, recalcitrant nail and joint psoriasis, successfully treated with secukinumab.

Keywords: nail disorders; psoriasis; secukinumab; therapy-systemic.

Publication types

Case Reports

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
Arthritis, Psoriatic / drug therapy*
Child
Female
Humans
Nail Diseases / drug therapy*
Nail Diseases / etiology
Nail Diseases / pathology

Substances

Antibodies, Monoclonal, Humanized
secukinumab